ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$59.66 USD
-0.72 (-1.19%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $59.68 +0.02 (0.03%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$59.66 USD
-0.72 (-1.19%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $59.68 +0.02 (0.03%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth C Momentum C VGM
Zacks News
Are Medical Stocks Lagging Argenx (ARGX) This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 9.68% and 8.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to ANI (ANIP) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for ANI (ANIP), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by higher Exparel sales.
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
by Zacks Equity Research
Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.
Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Alkermes (ALKS) reports mixed second-quarter 2024 results. Earnings and revenues decline year over year.
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
by Zacks Equity Research
The FDA rejects the accelerated approval pathway for Agenus' (AGEN) BOT/BAL combination in relapsed/refractory microsatellite stable colorectal cancer patients.
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
by Zacks Equity Research
TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
by Zacks Equity Research
Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
by Zacks Equity Research
Ultragenyx (RARE) reaches alignment with the FDA regarding the pivotal phase III study design and endpoints for GTX-102 for Angelman syndrome, which is scheduled to be initiated later this year.
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
by Zacks Equity Research
Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, which is being studied for two different cancer indications.
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
by Zacks Equity Research
Arcutis (ARQT) rises 30.9% in a month after the label expansion of its marketed product, Zoryve cream 0.15%, for the AD indication in adult and pediatric patients aged six years and older.
Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why
by Zacks Equity Research
Lisata (LSTA) is progressing well with developing its lead investigational pipeline candidate, certepetide, which is being studied for various cancer indications.
Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
by Zacks Equity Research
Beam Therapeutics' (BEAM) current chief financial officer, Terry-Ann Burrell, is set to step down from her role on Aug 9. The stock falls 4.7%.
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
by Zacks Equity Research
Alimera (ALIM) is set to be acquired by ANI Pharmaceuticals for approximately $381 million in upfront consideration. The transaction is expected to close in the third quarter of 2024.
Strength Seen in Gilead (GILD): Can Its 8.5% Jump Turn into More Strength?
by Zacks Equity Research
Gilead (GILD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Implied Volatility Surging for ANI Pharmaceuticals (ANIP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to ANI Pharmaceuticals (ANIP) stock based on the movements in the options market lately.
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
by Zacks Equity Research
AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
by Zacks Equity Research
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) gains 21% on May 20 after the EC decided against adopting the negative CHMP opinion of January 2024 on the annual renewal of the conditional approval of Translarna.
Sanofi (SNY) Signs Deal for AI-Powered Drug Development
by Zacks Equity Research
Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
Roche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.